resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases. Strong scientific evidence suggests that aging is regulated by specific biochemical pathways. Medicines that target these biochemical pathways, such as the TORC1 pathway, may prevent or treat a variety of aging related diseases. resTORbioâs lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including immune, neurologic and cardiac function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging related diseases. Source
No articles found.
Global Cancer Technology (GCT) is an emerging medical technology company with nu...
Global Cancer Technology (GCT) is an emerging...
LHC Group, Inc. is a national provider of in-home healthcare services and innovati...
LHC Group, Inc. is a national provider of in-ho...
Molecular Templates is focused on the discovery, development, and commercializatio...
Molecular Templates is focused on the discovery...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
Join the National Investor Network and get the latest information with your interests in mind.